-
公开(公告)号：US11344605B2
公开(公告)日：2022-05-31
申请号：US16069676
申请日：2016-09-27
Applicant: Humanitas Mirasole S.p.A.
Inventor： Marinos Kallikourdis , Gianluigi Condorelli
Abstract: The present invention relates to the use of inhibitors of T cell costimulation and/or activation and/or function in the treatment and/or prevention of cardiac pathologies, in particular heart failure diseases, and/or of related symptoms.
-
2.发明申请公开(公告)号：US20170128200A1
公开(公告)日：2017-05-11
申请号：US15319362
申请日：2015-06-17
Inventor： Giorgio SOLDANI , Mattia GLAUBER
CPC classification number: A61F2/2415 , A61L27/18 , A61L27/507 , B29C41/003 , B29C41/08 , B29C41/085 , B29C43/003 , B29C43/02 , B29C43/36 , B29C43/52 , B29C2043/3665 , B29K2069/00 , B29K2075/00 , B29K2083/00 , B29L2031/7506 , B29L2031/7532 , C08L83/04
Abstract: A process for the manufacture of a heart valve of polymer material which provides for the deposition of a polymer solution comprising a copolymer which is preferably a copolymer of poly(carbonato-urethane) fluoridate (F-PCU) and intracatenary polydimethylsiloxane (PDMS), a PDMS with a functional group outside the chain and a solvent onto a mould using a spray technique associated with phase inversion.
-
公开(公告)号：US20220370608A1
公开(公告)日：2022-11-24
申请号：US17629139
申请日：2020-07-22
Inventor： Giuseppe PENNA , Maria RESCIGNO , Abbass DARWICH
IPC: A61K39/395 , A61P35/00 , G01N33/574
Abstract: The present invention relates to a suppressor or inhibitor of the expression and/or the activity of Chitinase 3-like 1 (CHI3L1) for use in the prevention and/or treatment of tumors, wherein said tumors are resistant to antibody-dependent cell-mediated cytotoxicity (ADCC) dependent therapies and/or for use in reducing the risk of developing resistance to antibody-dependent cell-mediated cytotoxicity (ADCC) dependent therapies.
-
公开(公告)号：US20230134376A1
公开(公告)日：2023-05-04
申请号：US17918097
申请日：2021-04-07
Applicant: HUMANITAS MIRASOLE S.P.A.
Inventor： Andrea DONI , Diego MORONE
IPC: A61B5/1455 , A61B5/145
Abstract: This invention pertains to a fluorescence lifetime imaging microscopy (FLIM)-based method for the quantitative three-dimensional (3D) imaging of the metabolic status of a lesion, including the acquisition of FLIM data of a least one anaerobic glycolysis marker. This method applies in particular to lesions such as wounds and tumours, and to markers such as the NADH/NAD+ ratio, the NAD(P)H/NAD+ ratio, the NADH/FAD ratio, the NAD(P)H/FAD ratio or the FADH/FAD ratio as a first marker, and their optional combination with a second marker such as pH, oxygen tension, glucose, pyruvate and lactate.
-
公开(公告)号：US20220054588A1
公开(公告)日：2022-02-24
申请号：US17415332
申请日：2019-12-18
Applicant: HUMANITAS MIRASOLE S.P.A. , HUMANITAS UNIVERSITY
Inventor： Andrea DONI , Alberto MANTOVANI
Abstract: Disclosed is the use of Serum Amyloid P component (SAP) polypeptides for the treatment of Eurotiomycetes fungi infections, in particular for aspergillosis and invasive aspergillosis, alone or in combination with pentraxin-3 (PTX3) polypeptides.
-
Patent Agency Ranking
公开(公告)号：US10907210B2
公开(公告)日：2021-02-02
申请号：US15104129
申请日：2014-12-16
Applicant: HUMANITAS MIRASOLE S.P.A.
Inventor： Luigi Laghi , Giuseppe Celesti
IPC: C12Q1/6886
Abstract: The present invention concerns a method for determining if a subject is affected by a colorectal or pancreatic cancer or for determining the stage and/or the progression of a colorectal cancer. By measuring the presence of a panel of m RNAs encoding for transcription factors/genes involved in epithelial to mesenchymal transition in a blood sample, wherein different mRNA levels of a set of genes comprising TWIST1, SLUG, ZEB2, ZEB1 and CDH1, are indicative of colorectal cancer or pancreatic cancer diagnosis, and/or of colorectal cancer stage at diagnosis, and/or of CRC metastatic progression after surgery. The invention concerns also the use of kits to work the method.
-
7.发明公开公开(公告)号：US20240150716A1
公开(公告)日：2024-05-09
申请号：US18550232
申请日：2022-03-18
Applicant: HEMERA S.R.L. , HUMANITAS MIRASOLE S.P.A.
Inventor： Ilaria DECIMO , Francesco BIFARI , Sissi DOLCI , Guido Francesco FUMAGALLI , Massimo LOCATI
IPC: C12N5/0786 , A61K35/15 , A61P25/00
CPC classification number: C12N5/0645 , A61K35/15 , A61P25/00 , C12N2500/02 , C12N2501/22 , C12N2502/30
Abstract: The present invention relates to an in vitro or ex vivo method for inducing a phenotypic and/or functional change in a population of mononuclear phagocytes isolated from biological samples. The method includes the incubation of the population in a culture medium which includes factors released from tumor cultures or explants. The incubation takes place under hypoxic conditions and the incubation induces a phenotypic and/or functional change in the mononuclear phagocytes of the population. The macrophages thus obtained assume a unique regenerative phenotype not present in other polarized phenotypes, including M2 macrophages. In addition, the invention relates to the use of the bioreactor thus produced for the regeneration of tissues, including neural tissue.
-
公开(公告)号：US20240123029A1
公开(公告)日：2024-04-18
申请号：US18275776
申请日：2022-02-08
Inventor： Alberto MANTOVANI , Cecilia GARLANDA , Barbara BOTTAZZI , Elisa VICENZI
CPC classification number: A61K38/178 , A61K45/06 , A61P31/14 , C12Q1/701 , C12Q2600/156 , C12Q2600/172
Abstract: The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-COV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-COV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).
-
公开(公告)号：US20230381291A1
公开(公告)日：2023-11-30
申请号：US18004831
申请日：2021-07-08
Inventor： Maria RESCIGNO , Alessia MELACARNE , Giuseppe PENNA
CPC classification number: A61K39/0011 , A61P37/04 , A61K2039/5154 , A61K2039/876
Abstract: The present invention provides antigen presenting cells (APC) carrying human tumor-associated peptides on the cell surface as well as immunogenic compositions including the tumor-associated peptides and/or the antigen presenting cells according to the invention. The immunogenic composition of the invention is useful as a vaccine in the prevention and/or treatment of a tumor disease, particularly melanoma and melanoma residual disease.
-
公开(公告)号：US20220323557A1
公开(公告)日：2022-10-13
申请号：US17634191
申请日：2020-08-07
Applicant: HUMANITAS MIRASOLE S.P.A. , HUMANITAS UNIVERSITY
Inventor： Marinos KALLIKOURDIS , Elisa MARTINI , Gianluigi CONDORELLI
IPC: A61K39/00 , C07K19/00 , A61K9/00 , A61P9/04 , A61P37/06 , C07K14/47 , C07K14/705 , C12N9/86 , G01N33/68
Abstract: The invention provides a new method for identifying peptide antigens relevant to a non-autoimmune disease involving T cell activation as well as novel peptides identified therefrom. The isolated peptides of the invention are useful in the diagnosis, prevention and/or treatment of a cardiovascular disease, more specifically heart failure (HF). The invention further provides a pharmaceutical composition comprising at least one isolated peptide of the invention and a pharmaceutically acceptable carrier, vehicle, excipient and/or diluent. The pharmaceutical composition of the invention is suitable to be orally administered as a tolerizing vaccine.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.013 seconds)
